

IQNovate Limited Begins Trading in U.S. Through Launch of ADRs

U.S. investors now have trading access to a contract drug development organization and scientific advisor to the global Biopharmaceutical industry.

SYDNEY, Australia, December 15, 2012

IQNovate Limited (NSX: IQN, OTC: IQNDY), a life science organization providing contract drug development services and scientific advice to the global Biopharmaceutical industry, announced today that it has listed and begun trading of its Level 1 American Depositary Receipts (ADRs).

Shares of the ADRs began trading on December 14, 2012 on the U.S. over-the-counter (OTC) market under the symbol IQNDY. The Company's ordinary shares trade on the National Stock Exchange of Australia under the symbol IQN and each ADR represents 10 ordinary shares.

IQNovate has appointed The Bank of New York Mellon as its Depositary Bank to establish and maintain the ADR facility. The ADRs will be tradable via licensed U.S. brokers in the ordinary course of trading.

"We are very excited to offer investors in the U.S. the opportunity to participate in the success of IQNovate Limited" commented George Syrmalis, Chief Executive Officer of IQNovate Limited. "As IQNovate Ltd is seeking to expand its operations in the Asia Pacific region simultaneously we are expanding our investor base from Australia to the USA". The primary benefit of establishing this program is to create a North American trading market for IQNovate and better access for U.S. investors to purchase IQNovate securities, further improving the liquidity of IQNovate shares."

For further information, please contact:

Con Tsigounis, Investor Relations. Telephone: +61 (2) 8239-5400

About IQNovate

IQNovate Limited is a life science organization, providing contract drug development services and scientific advice to the global Biopharmaceutical industry. The company also extends a premium advisory service to institutional capital investors on biotech investment strategy.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organizations.

IQNovate focuses on every segment of the drug life cycle, from the preclinical stage to clinical, right through to RRC, bridging science with business and beyond.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQNovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQNovate Limited